Home
EN / FR

Celyad Oncology

Home

ABOUT CELYAD ONCOLOGY

Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer

More Info About Celyad ONCOLOGY

Latest News

376_981be_rev-1

Celyad Oncology Presents Data Update from Phase 1 alloSHRINK Trial for CYAD-101 in mCRC at ASCO-GI Symposium

January 18, 2021
READ THE PRESS RELEASE

Celyad Oncology Appoints Marina Udier, Ph.D., to Board of Directors

January 11, 2021
READ THE PRESS RELEASE

Celyad Oncology Announces Equity Purchase Agreement for up to $40 Million with Lincoln Park Capital

January 7, 2021
READ THE PRESS RELEASE

Celyad Oncology Announces January 2021 Conference Schedule

January 5, 2021
READ THE PRESS RELEASE

Celyad Oncology Successfully Doses First Patient in Expansion Cohort of the CYAD-101 Phase 1 alloSHRINK Trial for mCRC

December 15, 2020
READ THE PRESS RELEASE

Celyad Oncology Provides Updates on Allogeneic and Autologous CAR T Programs at 62nd ASH Annual Meeting and Exposition

December 7, 2020
READ THE PRESS RELEASE

Celyad Oncology Announces Dosing of First Patient in Phase 1 IMMUNICY-1 Trial of CYAD-211 for Multiple Myeloma

December 4, 2020
READ THE PRESS RELEASE

Celyad Oncology to Participate in a Fireside Chat at the JMP Securities Hematology Summit

December 1, 2020
READ THE PRESS RELEASE

Celyad Oncology Announces Third Quarter 2020 Financial Results and Recent Business Highlights

November 10, 2020
READ THE PRESS RELEASE

Celyad Oncology to Present Updates from Allogeneic and Autologous CAR T Programs at 62nd ASH Annual Meeting and Exposition

November 4, 2020
READ THE PRESS RELEASE
Discover All News

Our SCIENCE

At Celyad Oncology, we are pursuing next-generation cellular immunotherapies by applying our broad understanding of immunology, novel technology platforms and modular design approach to drug discovery.

Read More About Our SCIENCE

Novel CAR T Immunotherapies

Advancing both allogeneic and autologous CAR T therapy candidates for the treatment of cancer

View Pipeline
Getty_488635681_lowres-1

Celyad Oncology@CelyadSA·
25 Jan

Join our CSO Dr. David Gilham at today's @KeystoneSymp virtual meeting where he will discuss 'Next-generation CAR T approaches exploiting natural killer receptor targeting' in #CellTherapy. Register here: https://keysym.us/VKSSmartCells21 #VKSSmartCells21 #eSymposia

View All

Stay informed about the latest news!

Sign up FOR our newsletter

By clicking on “send”, you accept that your data will be sent to us and processed by our provider in order to send you our newsletter. You can find more information on how we process your data in our Privacy Policy.